George Vandeman and Thomas Zindrick join Genelux board
Mr. Vandeman has also been named Vice Chairman. Mr. Vandeman retired in 2000 after five years at Amgen as Senior Vice President, General Counsel and Chairman of the Company’s Operating Committee.
During his tenure at Amgen, he was responsible for the Corporate Development and Product Licensing groups, the company’s legal department, as well as mergers and acquisitions and product licensing activities.
Immediately prior to joining Amgen, Mr. Vandeman was a senior partner and head of Mergers & Acquisitions for the international law firm of Latham & Watkins, where he worked for nearly three decades representing bidders, targets and financial advisors in corporate control transactions and advising Boards of Directors as to M&A and corporate governance matters.
Since his retirement from Amgen, he has been a principal in Vandeman & Co., a private investment firm.
Mr. Zindrick, also named to the Board of Directors, was recently appointed CEO and president of Genelux Corporation, succeeding founder and former CEO and President, Aladar A. Szalay, Ph.D.
Prior to Genelux, Mr. Zindrick was CEO of Amitech Therapeutic Solutions, Inc., a La Jolla, California based discovery and drug development company, and has also served as an independent consultant to Genelux Corporation on a number of legal and business-related matters.
He retired from Amgen in 2009 after a distinguished 16 year career, where he served as Vice President, Associate General Counsel, leading intellectual property, licensing and regulatory law teams that were instrumental in the licensing and development of six therapeutic products and numerous clinical candidates.
Mr. Zindrick also served as Chief Compliance Officer, reporting to the Board of Directors. ■